← Back to Search

pegsitacianine for Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by OncoNano Medicine, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Biopsy confirmed diagnosis, or a high clinical suspicion of a lung malignancy based on MRI, CT and/or PET imaging
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

This trial is testing a new cancer treatment where patients are given a single dose of a drug before surgery. The trial is open-label, which means that doctors and patients will know which treatment is being given.

Eligible Conditions
  • Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Patients experiencing at least one Clinically Significant Event (CSE)
Secondary outcome measures
Frequency and Severity of adverse events related to Pegsitacianine
Pegsitacianine fluorescence and imaging performance

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fluorescence imaging with pegsitacianineExperimental Treatment1 Intervention
Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
pegsitacianine
2021
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

OncoNano Medicine, Inc.Lead Sponsor
3 Previous Clinical Trials
248 Total Patients Enrolled

Frequently Asked Questions

~8 spots leftby Mar 2025